Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 8800 HSC Pkwy BRYAN TX 77807 |
Tel: | 1-646-2743580 |
Website: | https://www.ibioinc.com |
IR: | See website |
Key People | ||
Martin B. Brenner Chief Executive Officer, Chief Scientific Officer | Felipe Duran Chief Financial Officer |
Business Overview |
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. It is in the process of building its preclinical pipeline, which focuses primarily on immuno-oncology. Its pipeline includes IBIO-101, Endostatin E4, TROP-2 x CD3, MUC16, EGFRvIII, and CCR8. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors. |
Financial Overview |
For the six months ended 31 December 2023, Ibio Inc revenues increased from $0K to $50K. Net loss before extraordinary items decreased 47% to $9.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects General and Administrative Expense Settl decrease of 47% to $5.5M (expense), Research and development decrease of 44% to $2.9M (expense). |
Employees: | 26 as of Jun 30, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $25.75M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.05M as of Dec 31, 2023 |
EBITDA (TTM): | -$19.83M as of Dec 31, 2023 |
Net annual income (TTM): | -$20.77M as of Dec 31, 2023 |
Free cash flow (TTM): | -$19.19M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $10.68M as of Dec 31, 2023 |
Shares outstanding: | 8,515,226 as of Apr 1, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |